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   This study focus on synthesis of novel compounds as potential agents for 






   All intermediary and final crystalline products formed were thoroughly 
purified and characterized by Thin Layer Chromatography (TLC) and 
Melting points. Structures were elucidated on the basis of Infrared (IR) and 
Nuclear Magnetic Resonance (NMR) spectroscopy. 1-(4-(octylsulfanyl)-3-
(trifluormethyl)phenyl)guanidine was evaluated for in vitro antimicrobial 
activity on different fungal and bacterial strains. 
Abstrakt 
Tato studie se zabývá syntézou nových látek s potenciálem k léčbě mykóz, z 
nichž byly připraveny následující čtyři: 
1-(4-(octylsulfanyl)-3-(trifluormethyl)fenyl)guanidin,  
1,1-dimethyl-3-( 4-(octylsulfanyl)-3-(trifluormethyl)fenyl)guanidin,   
1-(4-(decylsulfanyl)-3-(trifluormethyl)fenylguanidin,  
3-(4-(decylsulfanyl)-3-(trifluormethyl)fenyl-1,1-dimethylguanidin. 
Všechny průběžné a finální krystalické produkty byly důkladně vyčištěny a 
jejich identita potvrzena tenkovrstvou chromatografií (TLC) a teplotou tání. 
Struktura produktů byla charakterizována prostřednictvím infračervené 
(IR) spektroskopie a nukleární magnetické rezonance (NMR). U 1-(4-
(octylsulfanyl)-3-(trifluormethyl)fenyl)guanidinu byla vyhodnocena in 
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          Fungal infection (mycosis) has drawn much attention since the 
middle of 20th century, with development of new chemotherapeutics1 and 
increased use of immunosuppressive drugs, tremendous rise of mycosis 
was observed. 
          Mycoses cause a wide range of diseases2 ranging from superficial 
infections which involves the skin to disseminating infections which 
involves the vital organs like the brain, heart and liver. Though mycoses can 
be overcomed by body’s self-defence mechanism together with effective 
medication, this has not been the case for immunocompromised victims 
like HIV patients, elderly and premature newborns, unlikewise, it has 
resulted to severe debilitating condition. Currently, the classical treatments 
available like amphotericin B, fluconazole, and griseofulvin are more 
challenged due to increasing resistance of fungal strains especially Candida 
species which plays a big role in the spread of most fungal infections. 
Today, fluconazole1 is less effective against mutant Candida species, with 
regards to this, there is an urgent need to develop novel compounds with 
less susceptibility to induced resistance. 
             Various studies have been carried out in the search of potential and 
effective alternatives to fungal treatment. Over the past 4 years, there has 
been an increased discovery of new lead structures with guanidine core 
which has had an impact in varied therapeutic3 effects including: 
chemotherapeutics, anti-diabetic, anti-inflammatory and CNS acting drugs.  
      Guanidine derivatives being one of the most studied chemical agent in 
recent discoveries, is the main target of our study. Our literature sources 
were obtained from Sci-Finder, Elsevier, Google scholar and literature 
books. Keywords used include: guanidine, phenylguanidine, arylguanidine, 






2. Theoretical Part 
    2.1. Mycosis 
     Mycosis is characterized as a disease caused by fungal strain which 
invades tissues by means of spores4 entering the body through the skin or 
inhalation. Clinical nomenclature2 for mycoses is classified based on site of 
infection, route of entry and type of virulence exhibited. Approximately 150 
out of 100,000 species of fungi5 are now recognized to be pathogenic to 
humans, of these strains the major causative ones in humans are Candida 
and Aspergilus species. 
     2.2. Current Trends in mycoses  
      The main focus is targeting on the severity of skin and invasive mycoses 
which contribute immensely to the rise of mycoses worldwide. Superficial 
mycoses constitutes a prevalence6 of 20-25% of all the skin mycoses 
globally, this clearly indicates a potential problem in the near future. 
Furthermore, opportunistic mycoses have increased significantly7 for the 
past two decades, posing a huge burden to immunosuppressed victims 
especially those undergoing organ transplant, HIV patients and those on 
long term immunosuppressive therapy like corticosteroids.  
    
    2.3. Current Therapy 
     The current approach in treating mycoses is based on the site of 
infection, mainly categorized as topical or systemic. Amphotericin B 
remains the gold standard in overcoming invasive and resistant mycoses 
effectively but it’s at highly disadvantage due to its toxic side effects such as 
nephrotoxicity in prolonged use. 
    Azole antifungals which include ketoconazole, fluconazole, itraconazole 
also play a big role in managing both systemic and skin infections, but the 
treatment is mostly less effective when fungal strains become mutant which 






2.4. Future Goal 
     In view of the epidemiological studies which indicate emergence of 
resistance and likeability of decreased response to current treatments, 
mycoses pose a significant global concern. Contributions towards 
development of new effective drugs has been the main focus as a result of 
increased prevalence of mycoses. Guanidines have received much attention 
due to their free availability8,9 in nature as well as vast applications in many 
fields including: pharmaceutics, agriculture, and organic chemistry. 
Furthermore, natural guanidines10display potent biological activities due to 
their unique structure.      
                 Maurizio1 et al., synthesized novel macrocyclic amidinourea 
derivatives(I), antimicrobial evaluation exhibited antifungal activity higher 
or comparable to fluconazole against Candida species and potent activity 
against fluconazole resistant Candida strains. 
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      Rukhsana9 et al., synthesized novel ferrocene-based guanidine 
derivatives (II). Crystallographic studies of these molecules revealed that 
existence of strong non-bonding interaction with biological macro-




                            
                                                 




                                                   
                                                            








    According to an article written by Nafees11 et al., tricyclic guanidine 
analogues of batzelladine K (III) were synthesized, one of the analogues 
with pentyl and methyl substituents on tricyclic ring exhibited broad 
spectrum antimicrobial activity. Other analogues exhibited varied 
antimicrobial spectrum.  
 
                                                     
                     
                                                    
 





       Muhammad12 et al. synthesized substituted pyridylguanidine 
derivatives (IV).IR, NMR and XRD studies revealed that synthesized 
guanidines are stabilized by intramolecular hydrogen bonds. All 
compounds exhibited excellent inhibition against Agrobacterium 
tumefaciens and aryl substituted pyridylguanidines with substitution at 
ortho and para position on the phenyl ring exhibited good to significant 
antifungal properties against A. niger and F. solani      
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        A study conducted by Guo Chun13 et al. on novel guanidine 
derivatives(V), exhibited strong killing effect on clinical pathogenic fungi 
and has potential to overcome defects of strong toxic and side effects as well 
as drug resistance. 
 
 
       
                                     
                                                                         
















3. Aim of the Project 
       This study aims to expound on the search of novel compounds which 
may be potential candidates in fungal therapy. The focus is on the synthesis 
of arylguanidines, specifically substituted phenyl guanidines. The following 
novel compounds will be synthesized in a step by step reaction as shown in 
the general reaction scheme: 
     1-(4-(octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine, 
     1, 1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluoromethyl) phenyl)guanidine, 
     1-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl guanidine,  
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 4.1. Materials and methods 
     All chemicals, solvents and reagents employed in this synthesis were 
used as obtained from the Aldrich manufacturer without further treatment. 
Structure identification was confirmed by melting point, Thin Layer 
Chromatography (TLC), Infrared (IR) and Nuclear Magnetic Resonance 
(NMR) spectroscopy. Reactions were monitored by TLC using silica-gel 
plates pre-coated with fluorescent indicator Silufol UV 254(Kavalier) with 
mobile phase constituting hexane, ethanol and triethylamine in ratio 
8:1:0.5. Melting points of the samples were measured with the help of 
Kofler apparatus and dried over phosphorous pentoxide (P2O5) at 61°C and 
66 Pa for 24 to 48 hours. IR spectra were measured on Germanium ATR 
Crystal on Nicolet 6700 FTIR spectrometer and NMR spectra were 





  2-chloro-5-nitrobenzotrifluoride will be employed as the starting chemical 
compound for the synthesis of all novel compounds. All reaction steps will 
be carried out under specified conditions. 2-chloro-5-nitrobenzotrifluoride 
will be made to react with alkylthiols in presence of copper14 to form 
alkylsulfanyl derivatives. The resulting products will undergo reduction 
process15 to form aniline derivatives. Following reduction, the aniline 
derivatives will be reacted with dry hydrogen chloride to form ammonium 
chloride salts. Subsequently, the ammonium chloride salts will be reacted 








4.3. Synthesis of a Catalyst 
  
 CuSO4 
.5H2O(s) +    Zn(s)  Cu(s) + ZnSO4 (aq) + 5H2O 
 
40.00 g (0.16085mol)of copper sulphate pentahydrate was mixed with 
140ml of water and the mixture was heated to dissolve. Following 
dissolution, the solution mixture was left to cool and 12.00g of zinc was 
then added to the mixture. The reaction was completed in 2 hours 
confirmed by color change from blue to colorless solution mixture. The 
mixture was then decanted by hot water and acidified by 5% of hydrochloric 
acid. Following acidification, the mixture was further decanted by ethanol 
solution to neutralize the product formed. The product was filtered and the 
residue was collected and dried in oven. 
 
Result 
Mass:  10.00g 












4.4. Synthesis of octylsulfanyl derivatives 
Step 1: Synthesis of -4-nitro-1-octylsulfanyl-2-trifluoromethyl 
benzene   
 
           









      
 39.82g (0.2881mol) of potassium carbonate, 120ml of dimethylformamide, 
3.05g (0.0480mol) of copper, 20ml (0.1152mol) of octanethiol and 25.00g 
(0.1108mol) of 2-chloro-5-nitrobenzotrifluoride  were mixed together and 
heated in an oil bath at 150°c.Reaction was completed in 8hrs confirmed by 
TLC chromatography .  
The mixture was filtered, water was added to the filtrate and kept in 
refrigerator. Crystals formed were purified by recrystallization from 
ethanol. Final crystals formed were dried and analyzed. 
Result 
Mass: 12.32g    
Yield: 33%     




















































































































































































































































































































































Step 2: Synthesis of 4-octylsulfanyl-3-trifluoromethylaniline 
 
 







S C8H17C8H17  
         
 10.00g (0.0298mol) of 4-nitro-1-octylsulfanyl-2-trifluoromethylbenzene, 
28.25g (0.149mol) of tin (II) chloride and 28ml of ethanol were mixed 
together and heated under reflux condition with nitrogen gas at 70°c for 
8hrs. 
        The product was left to cool and later alkalized with 50% of sodium 
hydroxide solution. It was then extracted three times to ethylacetate. The 
extract was dried by sodium sulfate and distilled off. Residual product was 
further extracted to hexane and then kept in refrigerator. Crystals formed 
were purified by recrystallization from ethanol. The final crystals were 
dried and analyzed. 
Result 
Mass: 6.00g 
 Yield: 66%     






















































































































































































































































































































































    5.00g (0.0164mol) of 4-octylsulfanyl-3-trifluoromethylaniline and 100ml 
of ether were mixed and stirred to dissolve.  The solution mixture was then 
let to cool in an ice bath for 30min.Dry hydrogen chloride was bubbled 
through the solution mixture. The crystals formed were filtered off, dried 
and analyzed. 
Result 
Mass: 2.77g  
Yield: 49%  
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0.50g (0.0015mol) of 4-octylsulfanyl-3-trifluoromethylammonium chloride 
was mixed with 0.10g (0.0023mol) of cyanamide and heated at 
120°C.Reaction was completed in 90minutes confirmed by TLC 
chromatography. 
   The product was dissolved in water and acidified with nitric acid. 
Following acidification, the solution mixture was left to crystallize in 
refrigerator. Crystals formed were purified by recrystallization from water. 

















































































































































































































































































































Step 4b: Synthesis of 1,1-dimethyl-3-(4-(octylsulfanyl)-3-
(trifluoromethyl)phenyl)guanidine 
   
 


















     
 
 0.50g (0.0015mol) of 4-octylsulfanyl-3-trifluoromethylammonium 
chloride was mixed with 0.16g (0.0023mol) of N, N-dimethylcyanamide 
and heated at 120°c.Reaction was completed in 90 minutes confirmed by 
TLC chromatography. 
   The product was then dissolved in water and alkalized with 5% of sodium 
hydroxide solution. Following alkalization, the solution mixture was 
extracted three times in diethyl ether and ethylacetate. The extract was 
dried by sodium sulfate and distilled off. Residual product was dissolved in 
water, acidified with nitric acid and kept in refrigerator. Crystals formed 
were purified by recrystallization from water. Final crystals formed were 
dried and analyzed.   
Result 
Mass: 0.38g   


































































































































































































































































































































































4.5. Synthesis of decylsulfanyl derivatives 
Step 1: Synthesis of 4-nitro-1-decylsulfanyl-2-trifluoromethyl 
benzene             
       
 










 39.82g (0.2881mol) of potassium carbonate, 120ml of dimethylformamide, 
3.05g (0.0480mol) of copper, 24ml (0.1152mol) of decanethiol and 25g 
(0.1108mol) of 2-chloro-5-nitrobenzotrifluoride  were mixed together and 
heated in an oil bath at 150°C.Reaction was completed in 8hrs confirmed by 
TLC chromatography.  
            The mixture was filtered, water was added to the filtrate and kept in 
refrigerator. Crystals formed were purified by recrystallization from 
ethanol. Final crystals formed were dried and analyzed. 
Result 
Mass: 27.07g    
Yield: 67%     





























































































































































































































































































Step 2: Synthesis of 4-decylsulfanyl-3-trifluoromethylaniline 
 
 
             







S C10H21C10H21  
          
10.00g (0.0275mol) of 4-nitro-1-decylsulfanyl-2-trifluoromethylbenzene, 
26.07g (0.1395mol) of tin (II) chloride and 28ml of ethanol were mixed 
together and heated under reflux condition with nitrogen gas at 70°C for 
8hrs. 
        The product was left to cool and later alkalized with 50% of sodium 
hydroxide solution. It was then extracted three times in ethylacetate. The 
extract was dried by sodium sulfate and distilled off. Residual product was 
further extracted in hexane and then kept in refrigerator. Crystals formed 
were purified by recrystallization from ethanol. The final crystals were 
dried and analyzed. 
Result 
Mass: 8.66g 
 Yield: 94%     







Step 3: Synthesis 4-decylsulfanyl-3-trifluoromethylammonium 
chloride 
 
             
                













    8.00g (0.0239mol) of 4-decylsulfanyl-3-trifluoromethylaniline and 
100ml of ether were mixed and stirred to dissolve.  The solution mixture 
was then let to cool in an ice bath for 30min.Dry hydrogen chloride was 
bubbled through the solution mixture. The crystals formed were filtered off, 
dried and analyzed. 
Result 
Mass: 5.82g  
 Yield: 66 %  









































































































































































































































































































































































Step 4a: Synthesis of 1-(4-decylsulfanyl)-3-(trifluoromethyl) 
phenyl)guanidine 
 
                 

















0.50g (0.0014mol) of 4-octylsulfanyl-3-trifluoromethylammonium chloride 
was mixed with 0.09g (0.0027mol) of cyanamide and heated at 
120°c.Reaction was completed in 90minutes confirmed by TLC 
chromatography. 
   The product was dissolved in water and acidified with nitric acid. 
Following acidification, the solution mixture was left to crystallize in 
refrigerator. Crystals formed were purified by recrystallization from water. 
Final crystals formed were dried and analyzed.   
Result 
Mass: 0.45g 












































































































































































































































































































































































Step 4b: Synthesis of 3-(4-(decylsulfanyl)-3-(trifluoromethyl) 
phenyl)-1,1-dimethylguanidine 
 
           

















     
 
 0.5g (0.0014mol) of 4-octylsulfanyl-3-trifluoromethylammonium chloride 
was mixed with 0.15g (0.0027mol) of N, N-dimethylcyanamide and heated 
at 120°c.Reaction was completed in 90 minutes confirmed by TLC 
chromatogram. 
   The product was then dissolved in water and alkalized with 5% of sodium 
hydroxide solution. Following alkalization, the solution mixture was 
extracted three times in diethyl ether and ethylacetate. The extract was 
dried by sodium sulfate and distilled off. Residual product was dissolved in 
water, acidified with nitric acid and kept in refrigerator. Crystals formed 
were purified by recrystallization from water. Final crystals formed were 
dried and analyzed.   
Result 
Mass: 0.40g   
































































































































































































































































































































































   In this project, novel compounds were synthesized according to the lab 
protocols employed in the synthesis of guanidine derivatives.  
    In the first step on the synthesis of alkylsulfanyl derivatives i.e. 4-nitro-1-
octylsulfanyl-2-trifluoromethylbenzene and 4-nitro-1-decylsulfanyl-2-
trifluoromethylbenzene and in the second step on the synthesis  of aniline 
derivatives i.e. 4-octylsulfanyl-3-trifluoromethylaniline, was quite 
challenging in that, crystals formed melted at room temperature and 
therefore making it difficult to measure the melting points of these 
intermediary products. 
      In the third step on the synthesis of ammonium chloride salts i.e.4-
octylsulfanyl-3-trifluoromethylammonium chloride and 4-decylsulfanyl-3-
trifluoromethylammonium chloride, was interesting in that, coloured 
crystals were formed easily and therefore it was easier to work with the 
crystals. 
       In the final step, the synthesis of guanidine derivatives was faced with 
some trials especially in the synthesis of dimethylguanidine derivatives i.e. 
1,1-dimethyl-3-(4-(octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine and 
3-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl)-1,1-dimethyl guanidine. 
Typical synthesis of dimethylguanidine according to the protocol, the 
solution mixture after heating reaction is alkalized to form crystals, 
unfortunately formation of crystals were unsuccessful and therefore 
guanidine nitrate derivatives were synthesized by acidifying the water 
solution of the dimethylguanidine derivatives. 
   
      Purification of products was achieved by dissolution of products in hot 
water or hot ethanol with small amount of charcoal in relation to their 
solubility in respective solvents. In the case of purification of guanidine 
derivatives, products were dissolved in hot water while in the case of 
alkylsulfanyl and aniline derivatives, products were dissolved in hot 




analyzed and confirmed by TLC, melting points, infrared and NMR 
spectroscopy. 
 
       1-(4-octylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine was evaluated 
for antimicrobial activity on fungal and bacterial strains in the department 
of microbiology and medical biology, Faculty of Pharmacy. The results 
obtained portrayed varying MIC in µmol/L for different strains. 
          Fungal strains with respective MIC included: Candida albicans 
(15.62), Candida tropicalis (7.81), Candida krusei (7.81), Candida glabrata 
(7.81), Trichosporon asahii (15.62), Aspergillus fumigates (15.60), Absidia 
corymbifera (31.25), Trichophyton mentagrophytes (7.81) 
         Bacterial strains with respective MIC included: Staphylococcus aureus 
(3.9), Staphylococcus aureus –MRSA (3.9), Staphylococcus epidermidis 
(3.9), Enterococcus sp. (7.81), Escherichia coli (15.62), Klebsiella 
pneumonia (15.62), Klebsiella pneumonia-ESBL (15.62), Pseudomonas 
aeruginosa (15.62) 
 














 The following novel compounds were successfully synthesized according to 
the given protocols:    
1-(4-(octylsulfanyl)-3-(trifluoromethyl) phenyl)guanidine, 
1, 1-dimethyl-3-(octylsulfanyl)-3-(trifluoromethyl phenyl)guanidine,  
1-(4-(decylsulfanyl)-3-(trifluoromethyl)phenyl)guanidine,  
3-(4-(decylsulfanyl)-3-(trifluoromethyl) phenyl-1,1-dimethylguanidine. 
   The compound structures were confirmed by IR, NMR spectroscopy, 
melting points and TLC. 1-(4-octylsulfanyl)-3-(trifluoromethyl)phenyl) 
guanidine was proved to exhibit antimicrobial activity in fungal strains 
including: C.albicans, C.glabrata, and A.fumigatus and bacterial strains 
including: Escherichia coli, Staphylococcus aureus and Klebsiella 
pneumonia. 
     According to this study, arylguanidines may be promising agents in the 
therapy of mycoses and other therapies as well, further research is yet to be 
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